524572 — Pharmaids Pharmaceuticals Balance Sheet
0.000.00%
- IN₹1.02bn
- IN₹1.23bn
- IN₹278.82m
Annual balance sheet for Pharmaids Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | C2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 4.07 | 161 | 48 | 8.23 | 27.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 13.4 | 13.9 | 26.8 | 75.3 | 65.3 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 26.7 | 175 | 135 | 210 | 110 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.81 | 21.1 | 385 | 492 | 286 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 111 | 246 | 913 | 1,199 | 873 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 24.4 | 21.3 | 116 | 287 | 240 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 24.4 | 21.3 | 193 | 605 | 396 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 86.7 | 225 | 720 | 593 | 477 |
| Total Liabilities & Shareholders' Equity | 111 | 246 | 913 | 1,199 | 873 |
| Total Common Shares Outstanding |